Unknown

Dataset Information

Evaluation of iodine-123-labeled metaiodobenzylguanidine single-photon emission computed tomography/computed tomography based on the International Society of Pediatric Oncology Europe Neuroblastoma score in children with neuroblastoma


ABSTRACT:

Background

This study sought to examine whether iodine-123-labeled metaiodobenzylguanidine (123I-MIBG) single-photon emission computed tomography/computed tomography (SPECT/CT), which is based on the International Society of Pediatric Oncology Europe Neuroblastoma (SIOPEN) score, could improve the diagnostic efficiency of children with neuroblastoma (NB), and to compare the diagnostic ability of minimal residual disease (MRD) detection and 123I-MIBG SPECT/CT.

Methods

We retrospectively analyzed 238 scans of patients who underwent 123I-MIBG SPECT/CT at the Department of Nuclear Medicine, Beijing Friendship Hospital, from January 2021 to December 2021. The diagnostic study was not registered with a clinical trial platform, and the study protocol was not published. The stand

SUBMITTER:  

PROVIDER: S-EPMC10240022 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature